Lupus nephritis therapy options mature past induction-and-maintenance
Voclosporin and belimumab in lupus nephritis plus emerging mechanism programs are restructuring induction and maintenance therapy.
Lupus nephritis has been a corticosteroid-and-mycophenolate or cyclophosphamide induction category with maintenance immunosuppression for years. Voclosporin added in 2021 in combination with mycophenolate and corticosteroid, belimumab gained lupus nephritis approval, and obinutuzumab (anti-CD20) is reading out in pivotal data. The category has gone from a stable induction-and-maintenance frame to a competitive multi-mechanism prescribing landscape in three years.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is lupus nephritis?
- SnapshotLupus nephritis therapy reference (2026)